James Dunlop

James Dunlop

Associate

Technology Transactions

James Dunlop is an associate in the San Diego office of Wilson Sonsini Goodrich & Rosati, where he focuses on the life sciences, biotech, and medical device industries.

During law school, James studied abroad at Universidad Torcuato di Tella in Buenos Aires, Argentina, and interned at law firms in Chile and Argentina. Before attending law school, James served as an RQ-170 instructor pilot in the U.S. Air Force.

James is fluent in both English and Spanish.

Experience

James Dunlop is an associate in the San Diego office of Wilson Sonsini Goodrich & Rosati, where he focuses on the life sciences, biotech, and medical device industries.

James is fluent in both English and Spanish.

Education

J.D., UCLA School of Law, 2023
M.A., Legal Studies, American Military University, 2020
B.S., Astronautical Engineering, U.S. Air Force Academy, 2012

Admissions

State Bar of California
U.S. Patent and Trademark Office

Credentials

Education

J.D., UCLA School of Law, 2023
M.A., Legal Studies, American Military University, 2020
B.S., Astronautical Engineering, U.S. Air Force Academy, 2012

Admissions

State Bar of California
U.S. Patent and Trademark Office

Recent Insights

Client Highlights

On August 8, 2024, Recursion and Exscientia announced the companies have entered into a definitive agreement, combining Recursion, a leading clinical stage technology-enabled biotech company decoding biology to industrialize drug discovery, with Exscientia, a technology-driven clinical stage drug design and development company, committed to creating more effective medicines for patients, faster. Wilson Sonsini Goodrich & Rosati advised Recursion on the transaction.

Learn More

Bylined Articles

SatMagazine’s latest Blake Brief article, titled "A Hitchhiker’s Guide to Patent Law in Outer Space" and authored by Curt Blake, John Wehrli, Peter Bratton, Magnus Gan, James Dunlop, and Matthew Fleming, discusses the value of conducting pharmaceutical research and development in space. The article specifically examines Merck's development of "space crystals" for its blockbuster Keytruda antibody drug and suggests that future commercial space treaties should be flexible to navigate the questions and complexities around patenting inventions developed in space.

Learn More